Active Filter(s):
Details:
Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.
Lead Product(s): Cholic Acid
Therapeutic Area: Genetic Disease Product Name: Cholbam
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Mirum Pharmaceuticals
Deal Size: $445.0 million Upfront Cash: $210.0 million
Deal Type: Divestment July 17, 2023